RNAi represents a powerful technology to specifically downregulate the expression of target genes. For cancer research and therapy, an efficient in vivo delivery system is supposed to distribute RNAi to all tumour cells upon systemic administration. We present replication-competent murine leukaemia virus (MLV) vectors, which deliver RNAi to tumour tissue upon tail vein injection. In HT1080 cells stably expressing GFP or luciferase, GFP expression was suppressed by more than 80% and luciferase (luc) activity by more than 90%, even when only 0.1% of the cells were initially infected with reporter gene specific vectors. To demonstrate its potential, PLK1-and MMP14-specific small hairpin RNA expression cassettes were applied in the system. Upon infection, PLK1 and MMP14 levels were reduced on mRNA and protein level. MLV-shPLK1-infected cells were arrested in the G2-phase and underwent apoptosis. MLV-shMMP14-infected cells showed reduced MMP2 activity, as well as substantially reduced invasion and tumour growth. In vivo, MLV-shLuc silenced luc expression in HT1080-luc tumour tissue by more than 80% and MLV-shPLK1 reduced tumour growth substantially, demonstrating the therapeutic relevance of this system. This RNAi vector system allows long-term downregulation of target gene expression as well as efficient delivery to and distribution throughout tumour tissue in vivo.
INTRODUCTION
RNAi has become an important tool for target gene validation and functional genomic studies. The therapeutic potential of RNAi has been evaluated in numerous preclinical studies and more recently also clinical trials. 1, 2 The gene silencing efficiency of RNAi is affected by several factors. First, its sequence determines target gene selectivity, off-target effects and, in case of small hairpin RNA (shRNA), the efficiency of RNAi maturation. Second, the persistence of gene silencing is influenced by the division rate of the target cells. Cells with high division rates, such as tumour cells, exhibit shorter periods of reduced gene expression than resting cells, because siRNA is rapidly diluted during each cell cycle. 3 Lastly, the in vivo efficacy of RNAi mainly relies on the delivery method. Upon local multidosal administration, naked unmodified siRNA silences target gene expression in the lung, the eye or the central nervous system. [4] [5] [6] Systemic applications of RNAi, in contrast, are hampered by rapid degradation and renal excretion. 2 To improve systemic delivery, siRNA delivery vehicles based on conjugates, liposomes or nanoparticles are being developed. 2, 7 Alternatively, viral vectors, such as adenoviral vectors, AAV vectors and lenti-or retroviral vectors are being used encoding the genetic information for the RNAi of choice as shRNA. 8 Murine leukaemia virus (MLV) is a simple, well-characterised g-retrovirus, which has been used in numerous studies of cancer therapy and gene transfer. Due to its intrinsic inability to infect quiescent cells, MLV is especially suitable for cancer research as it preferentially infects tumour cells. Besides conventional replicationincompetent MLV-derived vectors, replication-competent retroviral (RCR) vectors also have been developed. These infect cells without any cytopathic effect, but spread through tissues and stably integrate their genome into that of the host cell thus offering the unique potential for persistence of the virus and a permanent anti-tumoural effect. 9 This way, genes of interest can be delivered to 95% of tumour cells in a solid subcutaneous tumour upon tail-vein injection of replicationcompetent MLV vectors. 10 Preclinical data on tumour mouse models demonstrated proof of principle for effective treatment of gliomas and colorectal cancer using MLV equipped with suicide genes after prodrug administration. [11] [12] [13] MLV accepts shRNA expression cassettes integrated in the 3¢-UTR of the env gene for several infection cycles without impaired replication kinetics. 14 Such viruses have been shown to deliver functionally active shRNA to target cells in vitro. Here we present an improved second-generation MLV based RNAi transfer system that is suitable for in vivo applications. This vector system encodes miRNA modified shRNA expression cassettes, which are more potent and less toxic. [15] [16] [17] [18] [19] We show efficient and stable knockdown of marker gene expression in vitro on the fibrosarcoma cell line HT1080 stably expressing GFP or firefly luciferase (luc). We further prove the applicability of this RNAi transfer system for gene function studies of tumour biology by suppressing polo-like kinase-1 (PLK1), which is tightly linked to cell proliferation and has been proposed as a diagnostic marker for several tumours 20 and matrix metalloprotease-14 (MMP14), a key target that promotes tumour cell invasion. 21 Efficient gene silencing in vivo with preestablished subcutanous tumours is demonstrated upon intravenous injection or local administration directly into the target tissue.
RESULTS
In the second-generation MLV-RNAi transfer system, shRNA coding sequences were put under control of the small nuclear promoter U6, equipped with a miRNA-specific loop and flanked by endogenous miRNA sequences to remodel the miR-30 primary transcript. 22, 23 The shRNA expression cassette was inserted between the env gene and the 3¢-long terminal repeat of the MLV genome encoded by pAZE-GFP, 24 resulting in pMLV-shRNA (Figure 1a) . We used either the env gene of the 4070A strain to provide a broad tropism for human and murine cells (aMLV-shRNA) or that of the ecotropic strain Moloney (MoMLV-shRNA). Initially, we inserted two cassettes coding for a GFP-specific shRNA or a non-specific randomised shRNA that does not target any mRNA in the mammalian genome, in both orientations into paMLV-shRNA, respectively. Stocks of the corresponding viruses were generated by transfection of HEK-293T cells resulting in titres of above 10 7 i.u. ml À1 . HT1080 cells were then infected at low multiplicity of infection (MOI) and once virus had spread to all cells, the genomic stability of the viruses was assessed by PCR analysis using primers flanking the shRNA cassette. Single PCR fragments of the expected size were obtained for both viruses carrying the shRNA cassette in plus orientation, that is, transcription from the U6 promotor is in the same orientation as transcription from the 5¢-long terminal repeat ( Figure 1b) . In contrast, PCR fragments of reduced size were detected for both viruses carrying the shRNA cassette in minus orientation, indicating that parts of the shRNA cassette had been deleted during virus replication. Sequence analysis confirmed a 138 bp deletion in the promoter sequence. Thus, for all further experiments viruses carrying the shRNA cassette in plus orientation were applied.
To evaluate the silencing efficiency of this second-generation MLV-shRNA viruses, we quantified the downregulation of the expression of the reporter proteins GFP and firefly luciferase. For each reporter, stably expressing HT1080 cells were generated by transduction with a lentiviral vector encoding GFP or luc. The cells were infected at different MOIs and reporter protein levels were quantified over time. Neither HT1080-Luc nor HT1080-GFP cells showed any significant changes in reporter protein levels when infected with the control virus aMLV-shNon (Figure 2 ). When aMLV-shGFP and aMLV-shLuc viruses were applied, GFP levels were downregulated to below 20% (Figures 2a and b) and luc levels to below 10% of control infected cells (Figure 2c ). These maximal extents of downregulation were reached for all MOIs applied, even when only 0.1% of the cells were initially infected. At the time point of maximal downregulation, all cells had become virus positive as determined by detection of the p30 antigen (data not shown). While identical maximal levels of downregulation were observed at the different MOIs, the kinetic of downregulation was MOI dependent. At high MOI, downregulation was more rapid, while at low MOI downregulation progressed more slowly. Moreover, the downregulation kinetics differed between the two reporters: for GFP the maximum extent of gene silencing was reached on day 12, for luc already on day 4 after infection, which can be referred to the much shorter half-life of luc in comparison to GFP. 3, 25 Next, we evaluated the potential of this RNAi-transfer system as tool for gene function studies in tumour biology. To investigate the effects of downregulation of tumour-promoting proteins, two different shRNAs specific for PLK1, a key player in cell cycle progression, were cloned into the amphotropic MLV, resulting into paMLVshPLK1-1 and paMLV-shPLK1-2. The activity of the viruses was assessed by downregulation of PLK1 protein expressed from an expression plasmid transfected into HEK-293-T cells (Figure 3a) . Transfection of the cells with paMLV-shPLK1-1 induced a substantial reduction of the PLK1 protein level down to 15% whereas paMLVshPLK1-2 administration evoked only a slight reduction (Figure 3a) . PLK1 is an important regulator of many cell cycle related events and its depletion induces G2 arrest and apoptosis. [26] [27] [28] To investigate the effect of PLK1 depletion on the cell cycle we analysed infected cells by flow cytometry. Cells infected with aMLV-shPLK1-1 were trapped in G2-phase at day 3 post infection. At day 5 post infection, 88% of cells were in the sub G1 phase, indicating induction of apoptosis, whereas for control virus-infected cells 38% were present in sub G1 (P¼0.0021, N¼3, Figure 3b ). Microscopic analysis confirmed the FACS data: aMLV-shPLK1-1 infected cells showed many conglobated cells typical for apoptotic processes, whereas control virus infected or uninfected cells were unaffected ( Figure 3c) .
Next, two different shRNAs specific for MMP14 were cloned, resulting into pMoMLV-shMMP14-1 and pMoMLV-shMMP14-2, respectively, and then tested for their silencing activity in HT1080-Rec1 cells, stably expressing the MoMLV receptor Rec1. 29 MMP14 expression was unimpaired on the mRNA and protein level, for all controls ( Figure 4 ). All MMP14 specific shRNAs, reduced mRNA and protein levels to different degrees. There was a nice correlation in the relative reductions on mRNA and protein level. Consistently, the strongest silencing was observed upon infection with MoMLVshMMP14-2, which reduced the MMP14 mRNA level to below 40% and the protein level to 12% of uninfected cells.
MMP14 is a key protease in the proteolytic activation of proMMP2, an important mediator of tumour cell invasion. 30, 31 To determine Figure 5c ). The data presented above show that the second-generation MLVshRNA vectors are able to distribute shRNA to cultivated cells. Next, we assessed the capability of this vector to deliver shRNA to tumour cells in vivo. Therefore, we applied the vector systemically into mice bearing subcutaneous HT1080-Luc tumours ( Figure 6a ). The tumours were isolated 25 days after injection to quantify the infection rate and to determine luc activity. Both, aMLV-shLuc and aMLV-shNon, had infected 100% of the tumour cells as determined on AZT treated re-cultivated tumour cells (data not shown). The genomic stability of aMLV-shLuc was confirmed by subcloning and sequencing of PCR fragments covering the shRNA expression cassette. The shRNA expression cassette was completely present in six out of six analysed clones. Two clones showed no sequence alterations, while in four clones between one and four nucleotide substitutions, most likely due to the PCR amplification step, were detected. While aMLV-shNon had no influence on the luc activity levels, tumours from aMLV-shLucinfected mice showed only 15.6 +/À4.53% of the activity present in uninfected tumours (Po0.01, Figure 6a ).
Finally, we investigated the potential of aMLV-shPLK1-1 in vivo. To this end, we directly applied the vector locally into mice bearing subcutaneous HT1080 tumours (Figure 6b ). In comparison to control-infected mice aMLV-shPLK1-1 significantly reduced tumour growth (P¼0.0019). The tumours were isolated 25 days after infection to quantify the infection rate. Both, aMLV-shPLK1-1 and RCR-mediated gene silencing T Schaser et al aMLV-shNon, had infected 100% of the tumour cells as determined on AZT-treated re-cultivated tumour cells (data not shown). The genomic stability of aMLV-shPLK1-1 and aMLV-shNon were confirmed by subcloning and sequencing of PCR fragments covering the shRNA expression cassette. The shRNA expression cassette was completely present in 17 out of 17 analysed clones. Five clones showed one to four point mutations whereas 12 clones were free of mutations within the shRNA expression cassette.
DISCUSSION
We present a second-generation RCR vector system that allows stable and continuous expression of RNAi and efficient delivery to tumour tissue upon intratumoral and systemic application. Several modifications contributed to the unique properties of this vector. First, the shRNA coding sequence was placed within the miR-30-derived shRNA shuttle backbone. 22, 23 This shuttle backbone was previously shown to prevent IFN-responsive gene expression in a retrovirus-based vector system. 15 Although not experimentally tested, it is likely that the miRNA-adapted shRNA used here is therefore more potent and less cytotoxic than conventional shRNA as also demonstrated by other studies. 16, 17 Second, overexpressed shRNAs might perturbate the miRNA network by occupation of shared, saturable RNAi proteins members such as exportin-5 or the RISC-complex. 18 MiRNA-adapted shRNA interferes to a lower extent with endogenous miRNA than conventional shRNAs, due to its more complex maturation process, which results in a lower steady-state level. 19 Moreover, the RCR vector guarantees a single copy delivery of the shRNA expression cassette per cell, which further prevents perturbation of the miRNA network.
Third, we identified the optimal orientation of the shRNA expression cassette to retain genetic stability of the virus. While stock virus titres were roughly identical for viruses carrying the shRNA cassette in either orientation, their genetic stability differed substantially: shRNA cassettes in 5¢-3¢ orientation were stable over several passages, whereas passage of viruses with the opposite orientation resulted in a 138 bp fragment deletion within the U6 promoter. This instability was unexpected as shRNA expression cassettes driven by the H1 promoter in this orientation were genetically stable. 14 A possible explanation for this difference in genetic stability is the higher activity of the U6 promoter, which could more effectively interfere with virus replication. 34 Deletions in RCR vectors had been observed previously to occur between direct and inverted repeats during reverse transcription. 24 However, this mode of deletion is unlikely here as no repeats were detectable around the deletion site. It is rather likely that shRNA transcription from the U6 promoter interfered with transcription of viral genomes from the 5¢-long terminal repeat. It is well conceivable that this interference is especially critical in infected cells where a single provirus copy is being transcribed for the formation of off-spring virus, but less critical in transfected producer cells where many copies of plasmid DNA per cell serve as template DNA for off-spring virus production. In line with this, the orientation of the shRNA cassette is not relevant in replication-deficient, retroviral vectors. 35 We quantified the knockdown efficiency of our vector system on indicator cells stably expressing GFP or luc. Silencing of stable, endogenously expressed (reporter) genes represents a more relevant model of RNAi application than transfection of reporter plasmids. 36 Moreover evaluation of sustained RNAi delivery necessitates sustained reporter gene expression. Several studies have tested RNAi delivery vehicles on cell lines stably expressing firefly luciferase and have reached similar knockdown efficiencies as we describe here. 36, 37 However, the knockdown was only transient in these studies although high amounts of siRNA/shRNA were applied. Our system, in contrast, mediates a dose-independent, sustained RNAi effect.
To demonstrate its applicability for endogenous genes relevant for tumourigenesis, PLK1 and MMP14 were chosen as targets. PLK1 belongs to the subfamily of human serine-threonine kinases and is involved in regulating cell progression through mitosis, where it is Representative pictures were taken at Â100 magnification.
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T Schaser et al implicated in centrosome cycle, spindle formation and chromosome segregation. In several kinds of tumours, PLK1 is highly overexpressed leading to extensive tumour growth. 38 In this study we were able to strongly reduce PLK1 protein levels and induce G2 arrest resulting in apoptosis by shRNA bearing aMLV (aMLV-shPLK1-1) in vitro. Furthermore, intratumorally injected vector significantly reduced tumour growth, underlining the potency of this system. MMP14 is a multifunctional enzyme involved in wound healing, angiogenesis and tumour cell invasion. 21 Moreover, MMP2, which is another MMP directly involved in tumourigenesis is proteolytically activated by MMP14. In our study, infection of tumour cells with the MMP14-specific RCR vector substantially reduced MMP14 expression on mRNA and protein level. Besides, we observed reduced proteolytic activity of the intermediate forms of MMP2. The reduction of MMP14 levels resulted in a considerably reduced invasion capability of the infected cells, which is in line with MMP14 being a key enzyme for degradation of the extracellular matrix and tumour invasion. 21, 39 Finally, when transplanted into immunodeficient mice, tumour formation and growth was significantly reduced for MMP14 silenced cells. This confirms the critical role of MMP14 for tumour growth. 40, 41 RNAi delivery systems can be applied directly into the target tissue or systemically. We have demonstrated the potential of our RNAi transfer system for both application routes. After intratumoral application of aMLV-shPLK1, a therapeutically relevant gene was silenced resulting in substantially reduced tumour growth. Systemic delivery offers the possibility of delivery to disseminated tissue and metastases that cannot be easily targeted. Currently available delivery vehicles lack high delivery rates upon intravenous application. Li et al. 42 demonstrated specific knockdown of luciferase expression to 20-30% in a lung metastasis mouse model with B16F10 cells stably expressing luciferase. As delivery vehicle nanoparticle-formulated siRNA was 
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intravenously applied. Compared with our vector system, RCR based RNAi delivery resulted in a stronger knockdown efficiency (more than 80%) even in a subcutaneous tumour, which is more difficult to access from the blood stream than tumour cells disseminated to the lung, which are better supplied with blood.
Additionally, the RNAi transfer system presented in this study offers the advantage of stable gene silencing. This enables long-term studies, particularly useful in situations when (therapeutic) effects are not detectable upon transient silencing. Furthermore, virus production is convenient and a single administration is sufficient to reach basically all target cells. MLV meets this prerequisite, because g-retroviruses preferentially replicate in tumour tissue. In addition, several layers of selective viral entry to tumour tissue have been developed by our group and others and may be added to enhance restricted shRNA delivery. 10, 43 Thus, the system presented in this study extends the repertoire of RNAi delivery vehicles, offering unique advantages for gene function studies and novel therapeutic strategies.
MATERIALS AND METHODS

Cell lines
HEK-293T (human embryonic kidney cells; ICLC HTL04001), HT1080 cells (human fibrosarcoma; ATCC, CCL-121), HT1080-Rec1 29 were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum and 1% glutamine. HT1080-Luc and HT1080-GFP were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum, 1% glutamine and 1 mg ml À1 G418 (Sigma-Aldrich, Taufkirchen, Germany). All cells were grown at 37 1C in humified atmosphere of 5% CO 2 .
To generate HT1080 cells stably expressing GFP or firefly luciferase, HT1080 cells were transduced with lentiviral vectors transferring the marker gene. Lentiviral vectors were generated by triple transfection with pCMVDR8.9, 44 pMD.G2 45 and the plasmid pHEIN, 46 encoding the bicistronic lentiviral transfer vector for GFP and neoR or pHLIN encoding the luciferase (pGL3-control, Promega, Mannheim, Germany) and neoR, respectively, as described previously. 47 Lentiviral vectors transferring luciferase and neoR were titrated by counting colonies after incubation for 12 days in medium supplemented with 1 mg ml À1 G418. Clonal HT1080 cells stably expressing GFP or luciferase were generated by transduction of HT1080 cells with a MOI of 0.1 and growing up of single cell clones in medium containing 1 mg ml À1 G418. After 12 days, marker gene positive clones were identified by luciferase assay (for HT1080-Luc) or FACS analysis (for HT1080-GFP).
MLV-shRNA encoding plasmids
The following shRNAmir-encoding plasmids (pSM2) were obtained from Open Biosystems (Huntsville, AL, USA): RHS1705 specific for firefly luciferase, RHS1706 for GFP suppression, RHS1764-9491622 (clone 1) and RHS1764-9697530 (clone 2) for MMP14, RHS1764-9691920 (clone 1) and RHS1764-9400329 (clone 2) for PLK1 and RHS1707 encoding a shRNA without homology to any known mammalian mRNA.
To generate amphotropic aMLV-shRNA-encoding plasmids (paMLVshRNA), the shRNA expression cassettes of the pSM2 plasmids were amplified by PCR using the following primers: miR_Bsi_V2_for 5¢-CGTACGAGGAAGA GGGCCTATTTCC-3¢ and miR_Not_rev 5¢-GCGGCCGCGTTTAAACGCATTA GTCTTC-3¢ for all MLV-shRNA(+) constructs and miR_Not_V2_for 5¢-GCG GCCGCAGGAAGAGGGCCTATTTCC-3¢ and miR_Bsi_rev 5¢-CGTACGGTTTA AACGCATTAGTCTTC-3¢ for MLV-shRNA(À) constructs. For the generation of aMLV-shRNA-encoding plasmids PCR fragments were subcloned, sequenceverified and ligated via BsiWI-NotI into pAZE-GFP, 24 thus replacing the IRES-GFP coding sequence of pAZE-GFP with the shRNA expression cassette. The Moloney-derived MoMLV-shRNA viruses were based on plasmid ZAPd-GFP, 24 which does not contain a BsiWI restriction site for cloning of the shRNA expression via BsiWI-NotI. Therefore, a BsiWI restriction site was introduced into ZAPd-GFP by exchanging the 1.3 kb NotI-ClaI fragment of ZAPd-GFP with the corresponding NotI-ClaI fragment of pAZE-GFP encoding the IRES-GFP sequence, the BsiWI restriction site and a 98 bp sequence for the C-terminal end of amphotropic env (conserved on the amino-acid level between amphotropic and ecotropic MLV, thus no change in amino acid sequence) resulting in ZAPdB-GFP. For the generation of MoMLV-shRNA-encoding plasmids, PCR fragments encoding shRNA cassettes were ligated via BsiWINotI into ZAPdB-GFP.
Virus production and titration
For virus production, HEK-293T cells were transiently transfected by calcium phosphate precipitation with the provirus-encoding plasmid. One day before transfection, 1.5Â10 7 cells were seeded in T175 flasks. One hour before transfection, medium was replaced by 12 ml fresh medium. A volume of 70 mg of plasmid DNA was diluted in H 2 0 (Sigma-Aldrich) to 1050 ml. A volume of 117 ml of 2.5 mol l À1 room temperature equilibrated CaCl 2 solution (Sigma-Aldrich) was added. A volume of 1167 ml of 2Â HEPES buffer (281 mmol l À1 NaCl; 100 mmol l À1 HEPES, 1.5 mmol l À1 Na2HPO4 (SigmaAldrich)) was added dropwise while vortexing. The precipitate was added to the cells. After overnight incubation, medium was exchanged by 20 ml fresh medium. After 24 h, virus was harvested by filtering supernatant through a 0.45 mm filter (Sartorius, Goettingen, Germany) and subsequently centrifuged at 3450 g at 4 1C for 24 h. The virus pellet was resuspended in phosphate- Figure 6 In vivo RNAi activity upon systemic and local application. (a) The 5Â10 5 HT1080-Luc cells were subcutaneously injected into SCID mice. Four days later, 2.9Â10 7 i.u. aMLV-shLuc or aMLV-shNon, were injected into the tail vain (n¼3). For normalisation of luc expression, uninfected mice bearing subcutaneous tumours were analysed in parallel (n¼4). Twenty-five days after intravenous injection, tumours were isolated, homogenised and luc activities were quantified. Luc activities of tumour lysates from infected mice were normalised to those of uninfected mice. To determine the background luc activity in tumour tissue, lysate from tumours derived from HT1080 cells were analysed as further control (right column). P-values compared to uninfected HT1080-Luc as calculated by unpaired t-test. (b) The 5Â10 5 HT1080 cells were subcutaneously injected into SCID mice. At a tumour size of 30 mm 3 1Â10 6 i.u. aMLV-shPLK1-1 or aMLV-shNon, were injected intratumoraly (n¼9). Tumour growth was assessed for the next 25 days. The data are expressed as the mean ± s.e.m. P-value was calculated by comparing the area under the curve using exact two-sided Wilcoxon rank-sum test. **Po0.01; ns, not significant.
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T Schaser et al buffered saline (PBS) and stored at À80 1C. Titration on HT1080 or HT1080-Rec1 was performed as described previously 29 to determine the number of infectious units per ml (i.u. ml À1 ). 
Genetic stability of the virus constructs
Gelatine zymography
A volume of 24 ml of conditioned medium was separated on a 10% SDS polyacrylamide gel containing 0.1% gelatine (Merck Chemicals Ltd., Nottingham, UK). Gels were washed twice in 2.5% Triton-100 (Serva, Heidelberg, Germany) for 30 min and incubated overnight in 50 mM Tris-Cl, pH 7.5, 200 mM NaCl, 5 mM CaCl 2 , 0.02% (w/v) Brij-35 at 37 1C for proteolysis to occur. The gel was stained with 0.5% Coomassie brilliant blue for 3 h and destained in 30% methanol, 10% acetic acid solution. 
Western blot
Quantitative real time PCR
To quantify MMP14 mRNA expression levels, total RNA of HT1080-Rec1 cells was isolated using the RNeasy Plus Mini Kit (Qiagen). Genomic DNA was removed using Qiagen RNase-Free DNase Set and samples were purified using Qiagen RNeasy MinElute Cleanup Kit according to the manufacturer's instructions. Quantitative RT-PCR reaction was performed using the QuantiFast SYBR Green RT-PCR Kit (Qiagen) on a LightCycler 2.0 System (Roche Applied Science, Mannheim, Germany). The following primers were used: MT1ORF-RT-left, 5¢-GGAATAACCAAGTGATGGATGG-3¢; MT1ORF-RT-right, 5¢-TTGT TTCCACGGAAGAAGTAGG-3¢. 40 MMP14 mRNA expression levels were normalised to b-actin using primers ACTB.sense 5¢-GAAATCGTGCGTGACA TTAAG-3¢ and ACTB.antisense 5¢-CTAGAAGCATTTGCGGTGGACGATGGA 
Invasion assay
The invasion activity of HT1080-Rec1 cells was determined using BD BioCoat Matrigel Invasion Chambers (24-well plate, 8-mm pore size PET membrane matrigel coated, BD Biosciences, Heidelberg, Germany) and BD BioCoat Control Cell Culture Inserts (24-well plate, 8-mm pore size PET membrane uncoated, BD Biosciences). Briefly, inserts were rehydrated with Dulbecco's modified Eagle medium for 2 h according to the manufacturer's instructions. Hydrated inserts were transferred to wells containing 0.75 ml of Dulbecco's modified Eagle medium supplemented with 5% fetal calf serum. Cells were harvested enzyme-free, washed with PBS, centrifuged at 138 g for 4 min at 4 1C, resuspended in Dulbecco's modified Eagle medium, and seeded into matrigel and control inserts at 0.8Â10 5 cells per insert in triplicates. After incubation for 6 h in a humified incubator at 37 1C, 5% CO 2 , non-invading cells were removed by scrubbing the upper surface of the membranes with a cotton tip swab. Invading cells on the lower surface of the membrane were fixed with methanol, stained with Bisbenzimid (1:1000, Sigma-Aldrich) and washed with PBS twice. Membranes were removed from the inserts and mounted in immersion oil on microscope slides and cover slipped. Five random fields per membrane were photographed at Â400 magnification and the mean number of cells was calculated. The relative invasion capacity was determined as the ratio of the number of invaded cells (from matrigel coated inserts) versus the number of migrated cells (from control inserts). The ratio obtained for infected cells was normalised to that of uninfected cells.
Cell cycle analysis by flow cytometry
Cells were harvested by trypsin digestion, washed with PBS and resuspended in ice-cold 70% ethanol for at least 5 h at 4 1C. Subsequently, cells were collected by centrifugation and resuspended in buffer containing 50 mg ml À1 propidium iodide, 0.1% Triton X-100 (v/v), 0.1 mM EDTA and 50 mg ml À1 RNase A. After 1 h incubation at 4 1C cell cycle, measurement was performed utilising a LSR II Fluorescence-Activated Cell Sorter (BD Bioscience, Erembodegem, Belgium). P-value was calculated using one-way ANOVA and adjusted according to Bonferroni.
Animal procedures
Experimental mouse work was carried out in compliance with the regulations of the German animal protection law. CB17 SCID female mice (6-to 8-week old) were obtained from Harlan Laboratories (Eystrup, Germany) and maintained under specific pathogen-free conditions. To establish subcutaneous tumours 5Â10 5 cells in 100 ml PBS were injected into the right flank of mice. For luc knockdown after systemic application, 2.87Â10 7 i.u. of aMLV-shLuc or aMLV-shNon in 100 ml PBS (n¼3) were injected into the tail vein of mice with subcutaneous HT1080-Luc tumours. For intratumoural PLK1 knockdown 1Â10 6 i.u. of aMLV-shPLK1-1 or aMLV-shNon in 50 ml PBS (n¼9) were injected directly into tumour tissue. Twenty-four days after virus application, mice were sacrificed and tumour tissue was isolated. Homogenised tissue was used for recultivation of tumour cells to determine the percentage of infected cells by immunocytochemistry as described previously 10 and for isolation of genomic DNA. For analysis of luc expression, tissue homogenate was lysed in 500 ml ice-cold Passive Lysis Buffer (Promega) in Lysing Matrix D tubes with a Fastprep homogenizer (MP Biomedicals, Illkirch, France). The tumour lysate was clarified by centrifugation at 12 000 g for 1 min at 4 1C and stored at À80 1C before quantifying luc activity.
